Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Company Performance - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,539 million in Q2 2025, with USD 2,017 million from the U.S. and USD 1,521 million from the rest of the world [1][5] - The company receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030 [2] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3]